Arrowstreet Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-265,562
Closed -$491K – 1818
2026
Q2
$491K Sell
265,562
-569,008
-68% -$1.39M ﹤0.01% 1759
2026
Q1
$1.78M Sell
834,570
-205,898
-20% -$490K ﹤0.01% 1423
2025
Q4
$2.53M Buy
1,040,468
+143,615
+16% +$509K ﹤0.01% 1337
2025
Q3
$3.4M Buy
896,853
+758,709
+549% +$2.22M ﹤0.01% 1309
2025
Q2
$343K Buy
+138,144
New +$266K ﹤0.01% 1814

Other funds holding BDTX

Arrowstreet Capital's BDTX Position: Q3 2026 in Review

Arrowstreet Capital sold out of Black Diamond Therapeutics (BDTX) in Q3 2026, closing a stake of 265,562 shares — an estimated $491K sold.

Arrowstreet Capital first reported a position in BDTX in Q2 2025 and held it in 5 quarters. The position peaked at $3.4M in Q3 2025. 110 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Arrowstreet Capital reported no remaining Black Diamond Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 265,562 Black Diamond Therapeutics shares in Q3 2026, an estimated $491K.
  • Arrowstreet Capital first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 5 quarters.
  • Arrowstreet Capital's Black Diamond Therapeutics position peaked at $3.4M in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.